{"nctId":"NCT02240030","briefTitle":"Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes","startDateStruct":{"date":"2014-11"},"conditions":["Idiopathic Parkinson's Disease"],"count":351,"armGroups":[{"label":"CVT-301 Low Dose","type":"EXPERIMENTAL","interventionNames":["Drug: CVT-301 Low Dose"]},{"label":"CVT-301 High Dose","type":"EXPERIMENTAL","interventionNames":["Drug: CVT-301 High Dose"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"CVT-301 Low Dose","otherNames":["Inhaled levodopa"]},{"name":"CVT-301 High Dose","otherNames":["Inhaled levodopa"]},{"name":"Placebo","otherNames":["Inhalation-grade lactose"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Idiopathic Parkinson's Disease (PD) diagnosed between the ages of 30 and 85 years;\n* Hoehn and Yahr Stage 1-3 in an \"on\" state;\n* Require levodopa-containing medication regimen at least 3 times during the waking day;\n* Experience motor fluctuations with a minimum of 2 hours of average daily \"off\" time per waking day (excluding early morning \"off\" time) and demonstrate levodopa responsiveness;\n* Are on stable PD medication regimen;\n* Total daily LD dose \\<1600 mg/day;\n* Able to perform a spirometry maneuver in the ON and OFF states;\n* Normal cognition confirmed by MMSE score â‰¥25\n\nExclusion Criteria:\n\n* Pregnant or lactating females;\n* Previous surgery for PD or plan to have stereotactic surgery during the study period;\n* History of psychotic symptoms requiring treatment, or suicide ideation or attempt within last year;\n* Known contraindication to the use of levodopa;\n* Any significant condition, severe concurrent disease, abnormality or finding that would make patients unsuitable or may compromise patient safety;\n* Any contraindication to performing routine spirometry.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Unified Parkinson's Disease Rating Scale (UPDRS) Part III","description":"Primary Efficacy Analysis: Change from Predose in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at 30 Minutes post-dose at Week 12 for CVT-301 High Dose versus Placebo (ITT Population). UPDRS Part III ranges from 0 minimum to 86 maximum, with lower scores indicating better movement. Units on a scale.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.83","spread":"1.506"},{"groupId":"OG001","value":"-5.91","spread":"1.500"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Achieving Resolution of an OFF to an ON State Within 60 Minutes.","description":"Examiner-assessed observation - Subject Achieving Resolution of an OFF to and ON state within 60 Minutes at TV4 - Observed","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"UPDRS Part III Motor Score at 20 Minutes","description":"Change from Predose in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at 20 Minutes post-dose at Week 12 for CVT-301 High Dose versus Placebo (ITT Population) and CVT 301 Low Dose versus Placebo. UPDRS Part III ranges from 0 minimum to 86 maximum, with lower scores indicating better movement. Units on a scale.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"97.5% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.47","spread":null},{"groupId":"OG001","value":"-9.04","spread":null},{"groupId":"OG002","value":"-6.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Who Improved PGIC With CVT-301 vs. Placebo at Week 12","description":"Patient Global impression of change at treatment visit 4 (week 12) by improvement category. Seven point Likert scale ranging from 1= much worse to 7= much better.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"UPDRS Part III at 10 Min.","description":"Change from Predose in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at 10 Minutes post-dose at Week 12 for CVT-301 High Dose versus Placebo (ITT Population). UPDRS Part III ranges from 0 minimum to 86 maximum, with lower scores indicating better movement. Units on a scale.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.16","spread":null},{"groupId":"OG001","value":"-6.45","spread":null},{"groupId":"OG002","value":"-4.18","spread":null}]}]}]},{"type":"SECONDARY","title":"PD Patient Diary","description":"Change in total daily OFF times for 3 consecutive days prior to week 12 visit compared to 3 consecutive days prior to baseline visit. Participants recorded On or Off state in 30 minute intervals during waking hours.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":null},{"groupId":"OG001","value":"-0.47","spread":null},{"groupId":"OG002","value":"-0.48","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":113},"commonTop":["Cough","Upper respiratory tract","Fall","Throat Irritation","Dyskinesia"]}}}